한글목차

대상포진 후 신경통 치료제 세계 시장 전망은 병원 약국, 온라인 약국, 소매 약국 시장에서의 기회로 인해 유망합니다. 세계 대상포진 후 신경통 치료제 시장은 2025-2031년 연평균 복합 성장률(CAGR) 4.0%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 대상포진 발병률 증가, 대상포진 후 신경통에 대한 인식 개선, 고급 치료 옵션 증가입니다.

• Lucintel의 예측에 따르면, 유형별로는 항경련제가 예측 기간 동안 높은 성장세를 보일 것으로 예측됩니다.
• 용도별로는 소매 약국이 가장 높은 성장이 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예측됩니다.

대상포진 후 신경통 치료제 시장의 새로운 동향

대상포진 후 신경통 치료 시장은 환자 관리와 치료에 혁명을 가져올 몇 가지 새로운 트렌드를 목격하고 있습니다. 이러한 추세는 기술 발전부터 환자 행동 및 치료 패러다임의 변화까지 다양합니다. 전 세계적으로 대상포진 후 신경통의 발병률이 증가함에 따라 이러한 추세는 시장의 진로에 영향을 미치고 있으며, 확대와 성장을 위한 새로운 길을 제시하고 있습니다.

• 원격 의료의 통합: 원격 의료는 PHN 관리, 특히 원격 모니터링 및 통증 관리를 위해 급성장하고 있는 추세입니다. 온라인 건강 플랫폼이 확산됨에 따라 환자들은 대면 진료 없이도 집에서 원격으로 전문의와 면담할 수 있게 되었습니다. 원격 의료는 지방이나 의료 서비스가 부족한 지역의 환자들에게 저렴하고 편리한 솔루션입니다.
• 맞춤의료: 맞춤의료는 PHN 관리에서 점점 더 중요한 역할을 하고 있으며, 의료 전문가가 환자 개인의 유전적 프로파일, 병력, 정확한 필요에 따라 맞춤형 치료를 할 수 있도록 하고 있습니다. 유전체 검사 및 정밀의학(Precision Medicine) 치료법 개발 증가 추세는 PHN 관리에 혁명을 불러일으키고 있습니다. 개인화된 전략은 임상의가 최적의 치료법을 선택할 수 있도록 도와주며, 이를 통해 환자의 결과를 개선하고 부작용을 최소화할 수 있습니다.
• 재생의료: 줄기세포 치료와 조직 재생을 포함한 재생의료 치료는 PHN 치료의 가능성으로 검토되고 있습니다. 이러한 치료법은 신경 손상을 치료하고 정상적인 기능을 회복시키려는 것으로, PHN 환자에게 장기적인 완화를 가져다 줄 수 있습니다. 이 방향의 연구는 이제 막 시작되었지만, 가까운 미래에 재생치료가 PHN 치료에 혁명을 가져올 것으로 기대됩니다.
• 병용요법: 약리요법과 비약리요법을 결합한 병용요법은 PHN 치료의 효과적인 접근법으로 각광받고 있습니다. 경구약과 국소치료, 신경자극기, 물리치료를 병용함으로써 환자들은 통증 감소와 삶의 질 향상을 경험하고 있으며, PHN 환자들에게 보다 종합적인 치료를 제공하고자 하는 의료 제공업체들에 의해 여러 치료법이 주목받으면서 시장 성장에 박차를 가하고 있습니다.
• 일반의약품: 환자가 의사를 만나지 않고도 경미한 증상을 치료할 수 있도록 일반의약품으로 PHN 치료제를 개발하려는 움직임이 증가하고 있으며, OTC 크림, 패치, 먹는 약은 편리함과 저렴한 가격으로 인기를 끌고 있습니다. 이러한 셀프 메디케이션 트렌드는 의료 접근성이 제한되어 있는 시장에서 특히 중요합니다.

이러한 새로운 트렌드로 인해 대상포진 후 신경통 치료 시장은 접근성 향상, 치료 옵션의 확대, 환자 맞춤형 치료 제공으로 변화하고 있습니다. 디지털 도구의 사용, 재생의료의 확대, 병용요법의 도입은 보다 효율적이고 효과적인 치료로 이어지고 있습니다. 이러한 트렌드가 계속 진화함에 따라 PHN의 치료 환경은 큰 변화를 겪게 될 것이며, 환자에게 더 나은 결과를 가져다주고 시장에 새로운 성장 기회를 창출할 것으로 예측됩니다.

대상포진 후 신경통 치료제 시장의 최근 동향

대상포진 후 신경통 치료 시장은 지난 몇 년 동안 큰 성장세를 보이고 있습니다. 대상포진 후 신경통은 여전히 전 세계적으로 수백만 명의 환자에게 영향을 미치고 있으며, 새로운 치료법과 개발이 진행되고 있습니다. 제약회사와 연구자들은 새로운 치료법, 유효성 향상, 환자 결과 개선에 초점을 맞추었습니다. 신약 출시, 첨단 기술, PHN을 특징짓는 장애를 유발하는 통증을 완화하는 치료 접근법의 개선으로 시장은 변화하고 있습니다.

• 의약품 개발의 발전: 최근 몇 년 동안 대상포진 후 신경통에 대한 신약 개발이 크게 진전되었습니다. 캡사이신 패치와 장시간 작용하는 오피오이드와 같은 새로운 약물의 도입은 대상포진 후 신경통의 치료에 큰 변화를 가져왔습니다. 이들 약물은 부작용을 줄이면서 지속적으로 통증을 완화하고 환자의 삶의 질을 향상시키는 것을 목표로 하고 있습니다. 또한, 새로운 약물 전달 시스템에 대한 연구 증가는 치료 효과를 높일 수 있는 잠재력을 가지고 있습니다.
• 비오피오이드 진통제의 등장: 비오피오이드 치료는 PHN에 대한 오피오이드 기반 치료법보다 안전한 대안으로 떠오르고 있습니다. 리도카인, 가바펜틴, 프레가발린과 같은 약물은 오피오이드의 위험 없이 신경통 완화에 효과적임이 입증되었습니다. 시장에서는 오피오이드 의존성 및 부작용에 대한 우려로 인해 이러한 치료법에 대한 수용이 확대되고 있으며, 비오피오이드 요법에 대한 수요가 증가하고 있습니다.
• 치료계획에 원격의료의 통합: 원격의료는 PHN의 치료를 극적으로 변화시켰습니다. 원격 의료 플랫폼은 현재 원격 진료를 제공하기 위해 널리 사용되고 있으며, 환자들은 자신의 상태를 더 잘 관리할 수 있게 되었습니다. 이를 통해 특히 지방에 거주하는 환자나 의료혜택을 제대로 받지 못하는 환자들의 의료 접근성이 확대되고, 환자의 경과 관찰과 치료의 실시간 조정이 용이해졌습니다.
• 신경조절 기술의 발전: 경두개 자기자극(TMS)이나 척수 자극과 같은 신경조절 요법은 PHN의 치료에 유망한 결과를 보여주고 있습니다. 이러한 치료법은 신경 활동을 변화시킴으로써 통증 인식을 감소시킵니다. 이러한 기술이 더욱 정교해지고 침습성이 낮아짐에 따라 치료 요법에 통합되어 기존 약물 요법이 실패한 경우 환자에게 대안을 제공할 수 있게 되었습니다.
• 개인 맞춤형 의료 전략: 개인 맞춤형 의료가 점점 더 강조되고 있으며, PHN 치료법을 개인에 맞게 조정하는 데 도움이 되고 있습니다. 유전자 연구의 발전으로 임상의가 환자의 유전적 체질에 따라 최적의 치료법을 선택할 수 있게 되었습니다. 이를 통해 보다 정확하고 효율적인 치료 요법이 가능해져 통증을 줄이고 부작용을 줄일 수 있습니다.

이러한 발전은 대상포진 후 신경통의 치료 시나리오에 혁명을 일으키고 있으며, 환자들에게 보다 효율적이고 안전하며 맞춤화된 치료 옵션을 제공합니다. 새로운 치료법과 혁신은 대상포진 후 신경통의 전반적인 관리를 개선하고, 과거에는 선택의 여지가 거의 없었던 환자들의 고통을 경감시키고 있습니다. 이러한 추세는 비오피오이드, 맞춤형, 기술 주도형 솔루션, 즉 효과와 환자 복지의 균형을 맞추는 헬스케어 분야의 큰 흐름이기도 합니다.

목차

제1장 주요 요약

제2장 세계의 대상포진 후 신경통 치료 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 대상포진 후 신경통 치료 세계 시장 동향(2019-2024년)과 예측(2025-2031년)
• 유형별
  • 항경련제
  • 피부 패치
  • 기타
• 용도별
  • 병원 약국
  • 온라인 약국
  • 소매 약국

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별 대상포진 후 신경통 치료 시장
• 북미의 대상포진 후 신경통 치료 시장
• 유럽의 대상포진 후 신경통 치료 시장
• 아시아태평양의 대상포진 후 신경통 치료 시장
• 기타 지역의 대상포진 후 신경통 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별
  • 용도별
  • 지역별
• 세계의 대상포진 후 신경통 치료 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 대상포진 후 신경통 치료 시장 능력 확대
  • 세계 대상포진 후 신경통 치료 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

영문목차

The future of the global post herpetic neuralgia treatment market looks promising with opportunities in the hospital pharmacy, online pharmacy, and retail pharmacy markets. The global post herpetic neuralgia treatment market is expected to grow with a CAGR of 4.0% from 2025 to 2031. The major drivers for this market are the rising incidence of shingles, the growing awareness of post-herpetic neuralgia, and the increasing availability of advanced treatment options.

• Lucintel forecasts that, within the type category, anticonvulsant is expected to witness higher growth over the forecast period.
• Within the application category, retail pharmacy is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market is witnessing some emerging trends that are revolutionizing patient care and treatment. These trends vary from technological advancements to changes in patient behavior and treatment paradigms. With an increasing incidence of PHN across the globe, these trends are influencing the path of the market and presenting new avenues for expansion and growth.

• Telemedicine Integration: Telemedicine is also a fast-growing trend for PHN management, particularly for remote monitoring and pain management. As online health platforms proliferate, patients can now remotely meet with specialists in the comfort of their own homes without requiring in-person consultations. Telemedicine is an affordable and convenient solution for patients in rural or underserved locations.
• Personalized Medicine: Personalized medicine is increasingly playing a vital role in the management of PHN, enabling healthcare professionals to customize therapies in accordance with the patient's individual genetic profiles, history, and precise needs. The increasing trend of implementing genomic testing and creating precision medicine therapies is revolutionizing PHN management. Personalized strategies are assisting clinicians in the selection of the best treatments, thereby enhancing patient outcomes and minimizing side effects.
• Regenerative Medicine: Regenerative medicine treatments, including stem cell therapy and tissue regeneration, are being explored as possible PHN therapies. These treatments seek to heal nerve injury and restore normal function, which might provide long-term relief for PHN sufferers. Studies in this direction are in nascent stages, but there is hope that regenerative therapies will revolutionize the treatment of PHN in the near future.
• Combination Therapies: Combination therapies, involving a combination of pharmacological and non-pharmacological therapies, are picking up steam as effective approaches to treating PHN. With the combination of oral drugs and topical therapies, nerve stimulation devices, or physical therapy, patients show improved pain relief and enhanced quality of life. The growing focus on multi-modal treatments is fueling market growth as providers seek to provide more holistic care to PHN patients.
• Over-the-Counter (OTC) Products: There is increasing momentum in the creation of over-the-counter PHN drugs so that patients can treat minor symptoms without seeing a doctor. OTC creams, patches, and oral medications are becoming popular due to convenience and affordability. This trend toward self-medication is particularly critical in markets where access to health care is restricted.

These new trends are transforming the post herpetic neuralgia treatment market by enhancing accessibility, expanding treatment options, and offering more individualized care to patients. The use of digital tools, the expansion of regenerative medicine, and the implementation of combination therapies are leading to more efficient and effective treatments. As these trends continue to evolve, the treatment landscape for PHN will likely undergo significant changes, offering better outcomes for patients and creating new opportunities for growth in the market.

Recent Developments in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market has witnessed massive growth in the recent past years. With the condition still impacting millions of patients globally, new treatments and developments are coming into view, resulting in better care and management. Drug firms as well as researchers are concentrating on new treatment methodologies, enhancing efficacy, and patient outcomes. The market is experiencing transformation fueled by novel drug launches, cutting-edge technologies, and improved therapeutic approaches to alleviate the disabling pain that characterizes PHN.

• Progress in Drug Development: In the last few years, there has been substantial advancement in the new drug development for Post-Herpetic Neuralgia. The introduction of new drugs such as capsaicin patches and long-acting opioids has significantly changed the treatment of PHN. These drugs target sustained relief from pain with less side effect, enhancing the quality of life in patients. Increased research into new drug delivery systems also holds the potential for enhancing treatment effectiveness.
• Emergence of Non-Opioid Pain Therapies: Non-opioid therapies are gaining momentum as a more secure option than opioid-based treatments for PHN. Drugs such as lidocaine, gabapentin, and pregabalin proved effective in alleviating nerve pain without the hazards of opioids. The market is experiencing growth in the acceptance of these therapies due to fears of opioid dependency and side effects fueling demand for non-opioid therapies.
• Telemedicine Integration in Treatment Plans: Telemedicine has transformed the treatment of PHN dramatically. Telemedicine platforms are now widely utilized to offer remote consultations, enabling patients to better manage their condition. This has opened up access to healthcare, particularly for rural or underserved patients, and has facilitated easier monitoring of patient progress and real-time adjustment of treatments.
• Advances in Neuromodulation Techniques: Neuromodulation therapies, including transcranial magnetic stimulation (TMS) and spinal cord stimulation, have shown promising results in treating PHN. These therapies work by altering nerve activity to reduce pain perception. As these techniques become more refined and less invasive, they are being integrated into treatment regimens, offering patients alternatives when traditional medications fail.
• Personalized Medicine Strategy: The growing emphasis on personalized medicine is assisting in tailoring PHN therapies to the individual. Breakthroughs in genetic research are making it possible for clinicians to select the most optimal therapies according to a patient's genetic makeup. This enables more precise and efficient treatment regimens, resulting in enhanced pain relief and reduced side effects.

These advancements are revolutionizing the post herpetic neuralgia treatment scenario by providing patients with more efficient, safer, and customized options. New treatments and innovations are enhancing the overall management of PHN, alleviating suffering for those who once had few alternatives. These advancements also represent a larger trend within the healthcare sector towards non-opioid, customized, and technology-driven solutions that balance both efficacy and patient welfare.

Strategic Growth Opportunities in the Post Herpetic Neuralgia Treatment Market

Post herpetic neuralgia treatment market is witnessing a number of growth prospects fueled by innovations, technological breakthroughs, and growing demand for improved solutions. The market is growing as increasing targeted therapies, developments in the mode of delivery of treatments, and growing emphasis on patient-centric care are providing opportunities to grow. Pharmaceutical organizations, healthcare providers, and investors are looking into major applications that will improve treatment and patient outcomes.

• Innovations in Topical Therapies: Topical therapies, including lidocaine and capsaicin patches, are emerging as a major growth opportunity in the PHN market. These treatments deliver localized pain relief with few systemic side effects and are thus a desirable choice for patients who want alternatives to oral drugs. Ongoing innovations in formulation and delivery systems will increase the efficacy and market penetration of topical therapies.
• Growth of Non-Opioid Therapeutics: With increasing need for non-opioid treatment of pain, there is evidently a chance of developing drugs which address the basic mechanisms of PHN without opioid dependency. Emerging molecules like newer anticonvulsants and antidepressants are being researched for better control of nerve pain and provide a new growth opportunity for pharmaceutical companies.
• Telemedicine and Remote Monitoring Solutions: Expansion of telemedicine and digital health technologies is providing opportunities to enhance patient care and treatment outcomes for PHN. Remote monitoring devices, wearable sensors, and mobile health apps can monitor symptoms and modify treatments in real time. This enhances the convenience and accessibility of PHN care, particularly for patients who live in remote locations or have mobility problems.
• Enhanced Neuromodulation Devices: The neuromodulation device market, including spinal cord stimulators and peripheral nerve stimulators, is likely to grow substantially. These devices provide a non-pharmacologic treatment option for PHN and are becoming increasingly popular due to their efficacy and decreased side-effect profile. Increased research and development will further enhance these devices, making them more precise and patient beneficial.
• Personalized Medicine in Pain Relief: Personalized medicine offers a sizeable growth opportunity through the targeting of treatments with genetic and molecular patient profiling. This strategy should maximize pain relief for PHN patients, so that the correct treatments are used for each. The incorporation of genomic information into treatment plans will enhance efficacy and reduce side effects, making personalized therapies a central market driver.

These growth opportunities reflect the trend towards more personalized, non-opioid, and technology-based solutions in the management of post herpetic neuralgia. As these applications mature, they not only enhance patient outcomes but also increase the scope of available treatment options. This makes the market more competitive and diverse, with increased emphasis on patient-centric care, which will fuel market growth in the next few years.

Post Herpetic Neuralgia Treatment Market Driver and Challenges

The post herpetic neuralgia treatment market is driven by a wide range of factors involving technology advancements, economic factors, and regulatory forces. Although many drivers are dominating the growth of the market, some obstacles such as regulatory barriers and treatment constraints are also affecting the rate of growth. Knowledge of these drivers and challenges is essential for stakeholders to steer the changing landscape of PHN treatment successfully.

The factors responsible for driving the post herpetic neuralgia treatment market include:

1. Growing Incidence of Herpes Zoster: One of the key drivers of demand for PHN treatments is the growing incidence of Herpes Zoster (shingles). With the aging of the global population, the number of cases of shingles and its complications, such as PHN, is on the rise. This is fueling the demand for effective treatments and therapies, leading to the expansion of the PHN treatment market.

2. Technological Advances in Treatment Modalities: The quick developments in neuromodulation technologies, customized medicine, and drug delivery devices are having a positive impact on the PHN treatment market. The new developments are making treatments more precise and effective, enhancing patient outcomes, and driving market growth. R&D is being heavily invested in by companies to introduce advanced technologies to the market.

3. Increased Awareness and Rising Diagnosis Rates: Public awareness regarding PHN and its effect on the quality of life of patients has increased over time. Increasing awareness is resulting in early diagnosis and treatment, which is fueling the demand for therapeutic solutions. Physicians are also learning to identify PHN at an early stage, further contributing to market growth.

4. Demand for Non-Opioid Pain Management: Owing to increasing fears over opioid addiction and dependence, demand for non-opioid pain management practices has picked up quite well. Increasing need for substitute treatment methods providing potent pain relief with minimal potential for addiction is pushing the usage of non-opioid treatment in PHN, stimulating the market growth.

5. Government Programs and Funding: Governments globally are realizing the cost of chronic pain conditions such as PHN, and many are providing incentives and funding to stimulate research on new treatments. This funding is stimulating innovation and speeding up the creation of better therapies.

Challenges in the post herpetic neuralgia treatment market are:

1. Regulatory and Approval Delays: One of the biggest challenges in the PHN treatment market is the long and complex approval process for emerging therapies. Delays in regulation can hinder the timely release of new and innovative therapies, limiting market growth and patient access to leading-edge therapies.

2. Limited Efficacy of Current Therapies: Although a variety of PHN treatments are currently available, patients still suffer from inadequate pain relief. The failure of universally effective therapies is one of the biggest challenges, and as a result, drug treatments fall short, creating unmet medical needs and ongoing demand for more effective treatments.

3. Cost of Treatment: The expensive nature of some PHN treatments, especially advanced neuromodulation equipment and customized therapies, continues to be a barrier for most patients. In other areas, insufficient insurance coverage and budgetary issues deter patients from obtaining the best treatment, which influences market adoption levels.

The post herpetic neuralgia market for treatment is expanding through rising incidence, technological innovation, and transition to pain management through non-opioid options. Despite these, limitations such as slow regulatory processes, limited effectiveness of existing therapies, and high costs of treatment are currently major impediments. Addressing these through innovation, changes in regulations, and enhanced affordability will be essential to further growth in the market and the creation of more effective PHN treatments.

List of Post Herpetic Neuralgia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies post herpetic neuralgia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the post herpetic neuralgia treatment companies profiled in this report include-

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

Post Herpetic Neuralgia Treatment Market by Segment

The study includes a forecast for the global post herpetic neuralgia treatment market by type, application, and region.

Post Herpetic Neuralgia Treatment Market by Type [Value from 2019 to 2031]:

• Anticonvulsants
• Skin Patch
• Other

Post Herpetic Neuralgia Treatment Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Post Herpetic Neuralgia Treatment Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Post Herpetic Neuralgia Treatment Market

In recent years, the post herpetic neuralgia treatment market has seen considerable growth in different countries like the United States, China, Germany, India, and Japan. The market has been driven by the growth in both pharmaceuticals and other treatments that address the chronic pain of PHN. Major growth drivers of this market include an aging population, greater knowledge about PHN, and innovation in new drugs and technologies. Challenges in the availability of treatment, cost, and regulatory barriers continue, specifically in developing countries. Technological advancements and changing patient requirements are both influencing the growth of the market.

• United States: The United States is still a dominant force in the post herpetic neuralgia Treatment Market, led by developments in pain management therapies. New approvals of drugs, especially new analgesics and nerve-directed treatments, have increased the range of treatments available to patients. The U.S. is also still at the forefront of the use of transcutaneous electrical nerve stimulation (TENS) devices and other non-pharmacological therapies. Furthermore, the growing incidence of herpes zoster infections and heightened awareness of PHN have also stimulated demand for therapies. Healthcare infrastructure and insurance for such treatments also boost market growth in the region.
• China: The post herpetic neuralgia Treatment Market in China is increasing at a rapid pace due to a growing healthcare industry and heightened awareness of PHN. The Chinese government has been enhancing healthcare access, which is predicted to increase the uptake of treatments. Access to sophisticated pain treatment, though, is still challenging in rural China. While drugs rule the marketplace, traditional Chinese medicine (TCM) therapy is being added to treatment plans more and more, with expanding interest in herbal and acupuncture therapies. This blend of conventional and new medicine is anticipated to be instrumental in the development of the market.
• Germany: Germany's post herpetic neuralgia Treatment Market is helped by its highly developed healthcare system and strong pharmaceutical sector. There has been an increase in new drug approvals and availability that help ease PHN pain, including topical and anticonvulsant medications. Germany also places significant emphasis on pain management research, leading to the establishment of non-invasive therapies such as neuromodulation and TENS devices. With the increasing population of the elderly, the need for good PHN treatments is bound to be on the rise. The robust healthcare base also provides improved access to these treatments, fueling market growth.
• India: India is confronted with an upsurge in PHN prevalence, mainly caused by a rise in shingles. The healthcare system of the country has been changing very fast, and treatment for PHN is now more accessible. Affordability is a major issue still, especially in rural India. New trends in the Indian market are the launch of generic forms of newer pain management medications, which have made these treatments affordable. In addition, campaigns regarding PHN and its treatment are picking pace, which may result in more patient interaction and treatment compliance, hence further driving market growth.
• Japan: Japan has a robust healthcare infrastructure, and the treatment scenario for post herpetic neuralgia is progressing steadily. Japan's market has experienced a rise in the use of sophisticated pain management therapies, such as nerve-blocking therapy and the use of technology in pain management. Japan also takes the lead in conducting research into novel drug therapy for PHN, with emphasis on efficacy and safety. The government has been initiating a move to get these drugs more widely available to the elderly, so that effective pain management is accessible to the increasing population of PHN patients.

Features of the Global Post Herpetic Neuralgia Treatment Market

Market Size Estimates: Post herpetic neuralgia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Post herpetic neuralgia treatment market size by type, application, and region in terms of value ($B).

Regional Analysis: Post herpetic neuralgia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the post herpetic neuralgia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the post herpetic neuralgia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the post herpetic neuralgia treatment market by type (anticonvulsants, skin patch, and other), application (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Post Herpetic Neuralgia Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Post Herpetic Neuralgia Treatment Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Post Herpetic Neuralgia Treatment Market by Type
  • 3.3.1: Anticonvulsants
  • 3.3.2: Skin Patch
  • 3.3.3: Other
• 3.4: Global Post Herpetic Neuralgia Treatment Market by Application
  • 3.4.1: Hospital Pharmacies
  • 3.4.2: Online Pharmacies
  • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Post Herpetic Neuralgia Treatment Market by Region
• 4.2: North American Post Herpetic Neuralgia Treatment Market
  • 4.2.1: North American Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.2.2: North American Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.3: European Post Herpetic Neuralgia Treatment Market
  • 4.3.1: European Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.3.2: European Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.4: APAC Post Herpetic Neuralgia Treatment Market
  • 4.4.1: APAC Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.4.2: APAC Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.5: ROW Post Herpetic Neuralgia Treatment Market
  • 4.5.1: ROW Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.5.2: ROW Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Application
  • 6.1.3: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Region
• 6.2: Emerging Trends in the Global Post Herpetic Neuralgia Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Arbor Pharma
• 7.3: Assertio Therapeutics
• 7.4: Endo Pharma
• 7.5: Teikoku Pharma
• 7.6: Teva
• 7.7: Mylan